Mile High Labs Cements its Place in the Regulatory CBD SpaceFirst Hemp-Derived CBD Ingredient Manufacturer to Enter Risk Management PhaseLONDON, Jan. 31, 2025 /PRNewswire/ -- Mile High Labs (MHL), a global leader in hemp-derived cannabinoid ingredients and finished products, is proud to announce its progression to the Risk Management Phase of the UK Novel Foods process. This milestone establishes MHL as the first and only hemp-derived CBD manufacturer to reach this advanced stage of regulatory approval, reinforcing its commitment to compliance, quality, and innovation.In early 2019, Mile High Labs was one of the first manufacturers in the CBD industry to receive GMP and ISO 9001 certifications. The Company's testing methodologies have been adopted by premier testing labs worldwide and have earned Mile High Labs five Emerald badges for excellence. This achievement builds upon five years of expertise in developing robust in-house data and refining proprietary processes—an effort unmatched by many competitors who depend on external or synthetic sources.When the FSA announced that CBD would be classified as a novel food ingredient, Mile High Labs prepared a dossier that contained manufacturing data, product specifications, stability data, quality control methodologies, and toxicological data to support the safe consumption of CBD. Unlike others relying on consortium data, Mile High Labs conducted its own detailed studies, ensuring a solid foundation of evidence for regulatory success."The compliance and integrity of our customers' products will always be our top priority," said Gary Korb, Director of Quality, Mile High Labs

Mile High Labs, provider of cannabidiol and cannabigerol ingredients intended to launch and expand new products, raised $25.50 million of venture funding from Highlands Venture Partners and other investors.